Jaguar Health out-licenses plant-based drug for schizophrenia

Plant-based concept

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded.

The agreement now includes the ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and for development with potential corporate partners.

Lisa Conte, Jaguar’s President and CEO, said: “The amended license agreement between Jaguar and Magdalena stipulates that Jaguar will receive 10% of all upfront payments, milestone payments, and similar payments received by Magdalena as part of any business development partnerships Magdalena enters for the Botanical Drug Candidate, excluding commercial milestones and R&D reimbursements, up to a defined cap amount.”

The US schizophrenia market is projected to grow to $8.06 billion by 2030, according to a market research report by Market Research Future.

Neuropsychopharmacology profile analysis shows the drug demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms.

Botanical or plant-based drug candidates

Magdalena, which is approximately 40% owned by Jaguar, is focused on advancing plant-based innovation for patients and on identifying the next generation of plant-based first-in-class agents for the treatment of mental health conditions.

The drug has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.

“Our team has always recognised and valued the unique and powerful knowledge indigenous and traditional peoples have about plants, ecosystems, and healing compounds,” said Steven King, Jaguar’s Chief Sustainable Supply and Ethnobotanical Research Officer and an Advisor to Magdalena. “Jaguar’s library of approximately 2,300 medicinal plants from tropical regions – developed over three decades by medicinal tropical scientific strategy team advisors, including ethnobotanists, physicians, pharmacologists, chemists, and experts in neuropharmacology from around the world – comprises a unique asset to drive drug discovery.

“The plant collection was assembled by teams of experts who conducted primary, first-hand field investigations and plant identification work in rainforest regions around the globe in addition to gathering data about traditional medicinal uses of plants from shamans and other Indigenous healers.”

Botanicals drugs are defined by the US Food and Drug Administration (FDA) as “products from plant materials, algae, macroscopic fungi, and combinations thereof.”

Many botanical drugs have a long history of safe use in traditional medicines, which may be documented and reviewed in scientific literature. Existing scientific literature on safety may accelerate the safety review process for a botanical drug, reducing the scope and financial burden for extensive safety studies.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free